Bikken Pronol Tablets (Bituowei) Chinese Instructions and Medication Guide

Biktarvy is a compound antiviral drug, consisting of Bictegravir (Bictegravir), emtricitabine (Emtricitabine) and tenofovir alafenamide (Tenofovir alafenamide, TAF) is composed of three ingredients and is a combined preparation of integrase inhibitors and nucleoside reverse transcriptase inhibitors. The drug was developed by Gilead Sciences and is widely used to treat HIV-1 infections in adults and adolescents aged 12 and above. Its single-pill compound design simplifies medication regimens and helps improve compliance and long-term treatment effects.

1. Drug ingredients and mechanism of action

Bictevir in Bikrena tablets is a third-generation HIV integrase strand transfer inhibitor that can block the integration of virus DNA into the host cell genome, thereby effectively inhibiting viral replication; emtricitabine and tenofovir alafenamide are both nucleoside reverse transcriptase inhibitors ( span>NRTIs), can competitively inhibit HIV reverse transcriptase activity and interfere with the process of transcribing viral RNA into DNA. The combined effect of the three can inhibit the virus life cycle at multiple targets and achieve rapid and lasting viral load control. Clinical data shows that Biktarvy can reduce HIV RNA in most patients to undetectable levels within 24 to 48 weeks, while reducing the risk of drug resistance.

2. Indications and scope of use

Bikernoprenol Tablets are suitable for adults and adolescents who have not received antiretroviral treatment (ART), and can also be used to change treatment plans for patients with stable viral loads and no history of drug-resistant mutations. The main advantage of this drug is that it does not need to be combined with other antiviral drugs, and one tablet can complete a complete treatment plan, simplifying the complex HIV management process. In addition, Biktarvy is effective against most common virus subtypes and also shows strong inhibitory effects on drug-resistant virus strains. Therefore, it is recommended as one of the first-line treatment options by international guidelines (such as DHHS, EACS).

3. Usage, dosage and medication guidance

The recommended dose is one tablet taken orally once daily (containing bictevir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg). It can be taken before or after meals and is not affected by food. It is recommended to take the medication at the same time every day to maintain stable drug concentration in the body. If you forget to take the medicine, you should take it as soon as possible; if it is close to the next time to take the medicine, skip the missed dose and do not take two pills at one time.

During the medication period, avoid taking antacids containing aluminum, magnesium, and calcium at the same time. If they are indeed used, they should be separated by at least two hours. For patients with impaired renal or liver function, they should consult a doctor before taking the drug and adjust the dose or monitor relevant indicators if necessary.

4. Adverse reactions and precautions

Overall, Biktarvy was well tolerated. Common minor adverse reactions include headache, nausea, fatigue, abdominal distension, mild liver enzyme elevation, etc. Individual patients may experience allergic reactions or changes in renal function, and serum creatinine, liver function and viral load need to be monitored regularly. During long-term use, potential metabolic problems such as changes in bone density and weight gain should be noted.

Contraindicated groups include those who are allergic to any ingredient, and those who are taking drugs that strongly induce CYP3A enzymes such as rifampicin, carbamazepine, phenytoin, etc., because these drugs will significantly reduce the blood concentration of bictivir and affect the efficacy. Pregnant or lactating women should follow medical advice and evaluate the risks and benefits when taking medication.

5. Clinical efficacy and patient management suggestions

In multiple III phase clinical studies, Biktarvy is better than or not inferior to the traditional triple regimen in terms of viral suppression rate, safety and drug resistance control. A significant decrease in viral load was observed in most patients at the 4th week of treatment, and the viral load in 48weeks exceeded 95%of the patients and was undetectable. For long-term users, the drug also shows significant advantages in maintaining immune function and reducing opportunistic infections.

It is recommended that patients follow up regularly during use to detectCD4+T lymphocyte count and viral load, so that doctors can evaluate the efficacy and adjust the plan. Maintaining regular medication and avoiding interruptions in treatment are the keys to maintaining long-term efficacy and preventing drug resistance.

Biktarvy (Biktarvy) is a new generation of integrated anti-HIVHIVTherapeutic drugs have become one of the standard solutions widely used around the world due to their high efficiency, safety and convenience. Correct medication methods, regular medication and long-term management under the guidance of doctors can help patients achieve lasting virus control and good quality of life.

Reference materials:https://www.drugs.com/